Key Info
OpenAI announced the acquisition of Orchestra Bio, a platform that helps biopharma teams coordinate the complex drug development process. The team will build on Rosalind, OpenAI's AI models and tools for life sciences research, to streamline those operations.
Highlights
- Orchestra Bio focuses on coordinating complex drug development workflows for biopharma teams
- OpenAI plans to integrate it with Rosalind, its life sciences AI models and tools
- Stated goal is to streamline operations and help new treatments reach patients sooner
- Orchestra Bio's Ashok Raj and team are joining OpenAI